New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?

about

New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?

Item

http://www.wikidata.org/entity/Q52599388

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@en

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@nl

type

Item

label

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@en

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@nl

prefLabel

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@en

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@nl

P1476

New Treatment Options for COPD ...... Endotypes or Treatable Traits?

@en

P2093

Ron Balkissoon

http://www.w3.org/2001/XMLSchema#string

P2860

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.

Inhaled corticosteroids in COPD and the risk of serious pneumonia.

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies

ACP Journal Club. Review: In COPD, fluticasone or budesonide increases serious pneumonia but not mortality.

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.

Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.

P304

72-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15326/JCOPDF.5.1.2018.0128

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29629407

http://www.w3.org/2001/XMLSchema#string

P932

5870743

http://www.w3.org/2001/XMLSchema#string